Conference Coverage

Patiromer Safe and Effective in Mild/Moderate and Severe Hyperkalemia

Washington, DC—Researchers, led by Matthew Weir, MD,  conducted a post hoc analysis to examine the efficacy and safety of patiromer based on the severity of baseline hyperkalemia. Patiromer, a sodium-free nonabsorbed potassium binder, uses calcium as the counter-exchange ion. Results were reported during a poster session at Kidney Week 2019 in a poster titled Efficacy and Safety of Patiromer by ... Read More »

Patiromer Safe and Effective Up to 1 Year Regardless of Patient Age

Washington, DC—Patiromer, a sodium-free, nonabsorbed potassium binder is approved for the treatment of hyperkalemia. Results from the OPAL-HK study demonstrated the efficacy and safety of patiromer in controlling serum potassium while maintaining renin-angiotensin-aldosterone system (RAAS) inhibitor therapy in younger and older adult patients with hyperkalemia over three months of treatment. The AMETHYST-DN study was a 52-week, multicenter, open-label trial of ... Read More »

Alport Disease in Girls

Inheritance of Alport disease, a multi-system disease, is most commonly linked to the X chromosome and has historically thought to be presymptomatic in young females. Previous studies and reports of outcomes have focused primarily on males and adult women. Selasie Goka, MD, and colleagues at Children’s Hospital of Philadelphia (CHOP), Pennsylvania, conducted a study designed to describe the clinical presentation ... Read More »

Nonadherence in Patients with Resistant Hypertension

Resistant hypertension is a common comorbidity among patients with kidney disease and is a risk factor for adverse cardiovascular outcomes. Patients with resistant hypertension also undergo increased screening for secondary hypertension. According to Gabrielle Emma Marie Bourque, MD, and colleagues, not all patients with apparent resistant hypertension have true resistant hypertension. Reports of nonadherence among patients with resistant hypertension range ... Read More »

Case Report: Resistant Hypertension with Renal Artery Stenosis

Following the publication of results of the Coral Study, medical management of secondary hypertension caused by renal artery stenosis is the standard of care. The Coral Study results found no difference in blood pressure control between medical management alone and medical management plus percutaneous intervention. However, because not all patients meet the inclusion criteria of the Coral Study results, management ... Read More »

Roxadustat Safe and Effective: Analyses of Pooled Results

Analyses of pooled results of phase 3 studies of roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD), including dialysis-dependent patients and nondialysis-dependent patients, were reported in a late breaker session at Kidney Week 2019. Robert Provenzano, MD, FACP, FASN, and Steven Fishbane, MD, reported the data during an oral presentation titled Pooled Efficacy and Cardiovascular ... Read More »

HIMALAYAS Study: Roxadustat versus Epoetin Alfa

The HIMALYAYAS trial was a phase 3 study of the efficacy and safety of roxadustat in the treatment of anemia in incident dialysis patients. Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates metabolism of iron. Results of the randomized, open-label, active-controlled study were reported during a presentation at Kidney Week 2019 by Robert ... Read More »

Hyperkalemia Excursions and Risk of Mortality: Analysis of DOPPS Results

There is an association between hyperkalemia and adverse clinical events in patients on hemodialysis identified by a single potassium serum potassium measurement or time-averaged potassium values. However, according to researchers, variability in serum potassium levels or excursions out of potassium target range are not reflected in the mean value of serial predialysis potassium measurements. The researchers utilized data from phases ... Read More »

Changes in ECG in Acute versus Chronic Hyperkalemia

Hyperkalemia resulting from kidney failure is associated with life-threatening arrhythmias. Researchers conducted a study to test the hypothesis that patients with chronic hyperkalemia from end-stage renal disease (ESRD) have fewer electrocardiography (ECG) changes and less arrhythmias than patients with acute hyperkalemia from acute kidney injury. The researchers reviewed 256 adult admissions from the Oakland University William Beaumont School of Medicine, ... Read More »

Hyperkalemia and Risk of RAAS Inhibitor Treatment Cessation

Nephrology Dialysis Transplantation. doi.org/10.1093/ndt/gfz263 There are few data available regarding the rates of hyperkalemia in users of renin angiotensin aldosterone system (RAAS) inhibitors and factors associated with treatment interruptions and cessation. Researchers, led by James B. Wetmore, MD, MS, identified RAAS inhibitor users in the linked UK Clinical Practice Research Datalink-Hospital Episodes Statistics data set, from 2009 to 2015. Treatment ... Read More »